Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Enanta Pharmaceuticals, Inc. (ENTA) is a Biotechnology company based in US with a market capitalization of $311.6M. Revenue declined 3.4% year-over-year and free cash flow was negative at -$32.2M. This page tracks ENTA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 131 employees · IPO Mar 21, 2013

Valuation

Valuation & price

$13.41as of May 17, 2026· -20.4% vs 52w high

P/E ratio

Latest-FY diluted EPS

4.81

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$16.85$11.67$6.49Jul 25Jan 26Jul 26
$6.4952-week range$16.85
Loading valuation history…

Fundamentals

Key fundamentals

$311.6M

Market cap

-3.4%

Revenue growth (YoY)

93.0%

Gross margin

-$32.2M

Free cash flow (USD)

$12.2M

Net debt

0.8%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$88.3M$65.3M

Free cash flow by year

20162025

$31.1M-$32.2M

Gross margin by year

20212025

100.0%93.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJul 2, 2026Filing

    Common Stock Sale Agreement

  • 8-K eventJun 23, 2026Filing

    Patent Invalidation

  • 8-K eventJun 18, 2026Filing

    Zelicapavir Update

  • Quarterly reportMay 13, 2026Filing

    10-Q Filed

  • 8-K eventMay 11, 2026Filing

    Earnings Release

Questions

Frequently asked questions

What is Enanta Pharmaceuticals, Inc.'s market cap?

Enanta Pharmaceuticals, Inc. (ENTA) has a market capitalization of $311.6M.

What is ENTA's P/E ratio?

A meaningful P/E ratio is not available for ENTA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ENTA's price-to-book (P/B) ratio?

ENTA trades at 4.81 times book value per share.

Are insiders buying ENTA stock?

SEC Form 4 filings show no open-market insider buys at Enanta Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.